Abstract
A number of studies have demonstrated that a moderate immune reaction may augment the response to chemotherapy. Two approaches are examined in the current report: (a) chemoimmunotherapy with viable L1210 cells that were antigenically altered by treatment with DTIC (L1210/DTCI), and (b) chemotherapy plus treatment with lymphocytes from mice immunized against L1210/DTCI. Treatment of the parental leukemias L1210 Ha and L1210 Cr with BCNU or cyclophosphamide in combination with viable antigenically altered tumor cells and with lymphocytes immunized against the antigenically altered tumor cells resulted in marked therapeutic responses. The observations suggest that these combined therapeutic modalities are worthy of investigation employing human tumors.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bonmassar E, Bonmassar A, Vadlamudi S, Goldin A (1970) Immunological alteration of leukemic cells in vivo after treatment with an antitumor drug. Proc Natl Acad Sci 66:1089–1095
Bonmassar E, Bonmassar A, Vadlamudi S, Goldin A (1972) Antigenic changes of L1210 leukemia in mice treated with 5-(3,3-dimethyl-l-triazeno)imidazole-4-carboxamide. Cancer Res 32:1446–1450
Campanile F, Houchens DP, Gaston M, Goldin A, Bonmassar E (1975) Increased immunogenicity of two lymphoma lines following drug treatment in athymic (nude) mice. J Natl Cancer Inst 55:207–209
Fefer A (1969) Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice. Cancer Res 29:2177–2183
Fefer A (1971) Adoptive chemoimmunotherapy of a Moloney lymphoma. Int J Cancer 8:364–375
Glynn JP, Halpern BL, Fefer A (1969) An immunochemotherapeutic system for the treatment of a transplanted Moloney virus-induced lymphoma in mice. Cancer Res 29:515–520
Glynn JP, Humphreys SR, Trivers G, Bianco AR, Goldin A (1963) Studies on immunity to leukemia L1210 in mice. Cancer Res 23:1008–1015
Goldin A, Humphreys SR (1960) Studies of immunity in mice surviving systemic leukemia L1210. J Natl Cancer Inst 24:283–300
Goldin A, Johnson RK (1974) Evaluation of actinomycins in experimental systems. Cancer Chemother Rep (part 1) 58:63–67
Goldin A, Humphreys SR, Chapman GO, Chirigos MA, Venditti JM (1960) Immunity of mice surviving leukemia (L1210) to antifolic resistant variants of the disease. Nature 185:219–221
Goldin A, Humphreys SR, Chapman GO, Venditti JM, Chirigos MA (1960) Augmentation of therapeutic efficacy of 3′5′-dichloroamethopterin against an antifolic-resistant variant of leukemia (L1210-M46R) in mice. Cancer Res 20:1066–1071
Goldin A, Humphreys SR, Venditti JM, Mantel N (1959) Prolongation of the lifespan of mice with advanced leukemia (L1210) by treatment with halogenated derivatives of amethopterin. J Natl Cancer Inst 22:811–823
Goldin A, Venditti JM, Mantel N (1961) Preclinical screening and evaluation of agents for the chemotherapy of cancer: A review. Cancer Res 21:1334–1351
Houchens DP, Bonmassar E, Gaston MR, Kende M, Goldin A (1976) Drug-mediated immunogenic changes of virus-induced leukemia in vivo. Cancer Res 36:1347–1352
Humphreys SR, Chirigos MA, Milstead KL, Mantel N, Goldin A (1961) Studies on the suppression of the homograft response with folic acid antagonists. J Natl Cancer Inst 27:259–276
Marshall EK Jr (1952) The dosage schedule of chemotherapeutic agents. Pharmacol Rev 4:85–105
Mihich E (1967) Synergism between chemotherapy and immunity in the treatment of experimental tumors. In: Spitzy KH, Haschek H (eds) Proc 5th Int Congr Chemother, vol 3. Wiener Medizinischen Akademie, Vienna, pp 327–331
Mihich E (1969) Modification of tumor regression by immunologic means. Cancer Res 29:2345–2350
Nicolin A, Bini A, Franco P, Goldin A (1974) Cell-mediated response to a mouse leukemic subline antigenically altered following drug treatment in vivo. Cancer Chemother Rep 58:325–330
Nicolin A, Canti G, Goldin A (1974) Adoptive immunotherapy in BALB/c×DBA/2 Cr F1 mice bearing an immunogenic subline of L1210 leukemia. Cancer Res 34:3044–3048
Nicolin A, Vadlamudi S, Goldin A (1972) Antigenicity of L1210 leukemic sublines induced by drugs. Cancer Res 32:653–657
Nicolin A, Vadlamudi S, Goldin A (1973) Increased immunogenicity of murine lymphatic tumors by pyrazole-4-carboxamide, 3 (or 5)-amino (NSC-1402; PCA). Cancer Chemother Rep 57:3–10
Riccardi C, Kline I, Peruzzi L, Goldin A (1977) Increased efficiency of antineoplastic agents in presence of antitumor immune responses in mice. Proc 5th Pharmacology-toxicology Symp, p 56
Schmid FA, Hutchison DJ (1971) Collateral sensitivity of resistant lines of mouse leukemias L1210 and L5178Y. Proc Am Assoc Cancer Res 12:23
Vadlamudi S, Padarathsingh M, Bonmassar E, Goldin A (1971) Effect of combination treatment with cyclophosphamide and isogeneic spleen and bone marrow cells in leukemic (L1210) mice. Int J Cancer 7:160–166
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Goldin, A., Nicolin, A., Bonmassar, E. (1980). Chemotherapy Immunogenicity. In: Mathé, G., Muggia, F.M. (eds) Cancer Chemo- and Immunopharmacology. Recent Results in Cancer Research, vol 75. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81491-4_29
Download citation
DOI: https://doi.org/10.1007/978-3-642-81491-4_29
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81493-8
Online ISBN: 978-3-642-81491-4
eBook Packages: Springer Book Archive